IMI to Boost Patient Involvement in its Activities

Innovative Medicines InitiativeThe Innovative Medicines Initiative (IMI) is creating a 'pool' of patient experts to strengthen the role and voice of patients in IMI activities at both strategic and operational levels. IMI has always involved patients in its work; now the plan is to take patient engagement at IMI to the next level.

IMI has involved patients in its projects and activities since the very beginning - as project partners, as members of the IMI Scientific Committee, and as speakers in our events, for example. Now, IMI wants to enhance the involvement of patients in all activities, for example by inviting them to provide input on scientific strategies; review project proposals; and assess the results of ongoing and closed projects.

To facilitate this, IMI is establishing a pool of patient experts that is open to a wide range of patients (and family members and carers) with a chronic illness or condition that is linked to IMI’s Strategic Research Agenda. The conditions for being part of the pool are simple and people who are interested in getting involved can submit an expression of interest via the IMI website.

When registering their interest, patients will be asked about their knowledge and experience of medical research and drug development, among other things. Whenever IMI has a task or activity that would benefit from patient input, the IMI Programme Office will turn to the pool to find the patient(s) with the most relevant knowledge and experience. For all tasks, patients will act in their personal capacity.

IMI Executive Director Dr Pierre Meulien said: "Patient engagement has always been a priority for IMI, and I am convinced that patients can and should be actively involved as equal partners in medical research and innovation. I hope that this pool of patient experts will provide both patients with a channel to influence research into their disease or condition, and IMI with information that will allow us to deliver projects that are truly aligned with patients’ needs."

Benefits for patients of getting involved in this new initiative include the opportunity to influence IMI’s activities on both strategic and operational levels; work alongside experts from other sectors (academia, industry, regulatory, etc.); raise the profile of patients as equal partners in research in the IMI community and beyond; and learn first-hand about the latest research developments in their disease area.

More information on the criteria for inclusion in the pool, how to apply, and the kinds of tasks participants could expect to be involved in, can be found in via this web page.

Deadline for submitting expressions of interest: 16 July 2019 at 17:00 CEST (Central European Summer Time / Brussels time)

IMI will hold a webinar for people interested in joining the pool on Tuesday 18 June at 14:00 CEST. Registration is free but obligatory via this link.

About the Innovative Medicines Initiative

The Innovative Medicines Initiative (IMI) is working to improve health by speeding up the development of, and patient access to, the next generation of medicines, particularly in areas where there is an unmet medical or social need. It does this by facilitating collaboration between the key players involved in healthcare research, including universities, pharmaceutical companies, other companies active in healthcare research, small and medium-sized enterprises (SMEs), patient organisations, and medicines regulators. This approach has proven highly successful, and IMI projects are delivering exciting results that are helping to advance the development of urgently-needed new treatments in diverse areas.

IMI is a partnership between the European Union and the European pharmaceutical industry, represented by the European Federation of Pharmaceutical Industries and Associations (EFPIA). Through the IMI2 programme, IMI has a budget of €3.3 billion for the period 2014-2020. Half of this comes from the EU’s research and innovation programme, Horizon 2020. The other half comes from large companies, mostly from the pharmaceutical sector; these do not receive any EU funding, but contribute to the projects 'in kind', for example by donating their researchers' time or providing access to research facilities or resources.

Most Popular Now

Artificial Intelligence Detects a New Cl…

Many mutations in DNA that contribute to disease are not in actual genes but instead lie in the 99% of the genome once considered "junk." Even though scientists have recently...

Essen University Medicine and Siemens He…

The Essen University Medicine, Germany's leading hospital company for digitalized medicine, and Siemens Healthineers, a world-leading medical technology company, plan to work together to develop the hospital of the future...

Final Cohort Selected For Pioneering Dig…

Propel@YH has announced the six start-ups to participate in its inaugural digital health accelerator programme, aimed at navigating the complex healthcare landscape and building an NHS-relevant business case. The Leeds-based...

New Kid on the Block: The Doctrina Acade…

The Doctrina Academy is a new service, developed by Doctrina, a video e-learning platform that reaches over 1,000,000 healthcare professionals (HCPs) from around the globe, helping them to switch ...

Gloucestershire Hospitals to Deliver EPR…

Gloucestershire Hospitals NHS Foundation Trust is moving to a 'clinical wrap' strategy to deliver an electronic patient record (EPR) and achieve the highest levels of digital maturity within five-years. The...

Efficacy and SilverCloud Health Supports…

A leading mental health service is using the digital mental health platform developed by SilverCloud Health to support a confidential NHS service for GPs in England. London-based Efficacy is offering...

Mobile Phone App Designed to Boost Physi…

Activity trackers and mobile phone apps are all the rage, but do they really help users increase and maintain physical activity? A new study has found that one mobile phone...

Application Period for an International …

The Master of Science (M.Sc.)in Medical Informatics (MMI) at European Campus Rottal-Inn (ECRI) in Pfarrkirchen - a branch of the Deggendorf University of Applied Sciences (THD - Technische Hochschule Deggendorf)...

NHS Prescribing is Back in the Spotlight…

Opinion Article by Dr Simon Hendricks, Product Innovation Manager and Clinical Strategy Lead, FDB (First Databank) Political will for better and safer prescribing in the NHS has fast gained momentum in...

Sectra to Provide Large Centralized Regi…

International medical imaging IT and cybersecurity company Sectra (STO: SECT B) has signed a five-year contract with North Tees and Hartlepool NHS Foundation Trust for the delivery of a regional...

IMI to Boost Patient Involvement in its …

The Innovative Medicines Initiative (IMI) is creating a 'pool' of patient experts to strengthen the role and voice of patients in IMI activities at both strategic and operational levels. IMI...